Azelastine/Fluticasone Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Azelastine/Fluticasone Supply in 2026

If your patients are reporting difficulty filling their Azelastine/Fluticasone prescriptions, they're not alone. The supply landscape for this combination nasal spray — marketed as Dymista — has shifted significantly heading into 2026.

This briefing covers what's driving the supply disruption, how it affects your prescribing decisions, and practical tools to help your patients maintain access to effective allergy treatment.

Timeline: How We Got Here

Azelastine/Fluticasone has had an evolving market history:

• 2012: FDA approved Dymista (azelastine HCl 137 mcg / fluticasone propionate 50 mcg per spray) for seasonal allergic rhinitis in patients ≥12 years. Later expanded to age ≥6.
• 2020: Generic Azelastine/Fluticasone became available after patent expiration, with Mylan (Viatris) as a major generic supplier.
• 2022: Astepro Allergy (azelastine 0.15%) became available OTC, giving patients direct access to the antihistamine component without a prescription.
• September 2025: Mylan (Viatris) announced discontinuation of its generic Azelastine/Fluticasone nasal spray (NDC 0378-3458-23), marked as "To Be Discontinued."
• 2026: Reduced generic supply is leading to intermittent pharmacy-level stockouts, particularly during spring allergy season.

Prescribing Implications

The current supply situation affects clinical decision-making in several ways:

Formulary and Coverage Changes

Many commercial insurance plans place Azelastine/Fluticasone on Tier 3 or Tier 4, with copays typically ranging from $40–$75. An increasing number of plans are implementing:

• Prior authorization requirements
• Step therapy protocols requiring documented failure of OTC alternatives (Flonase, Astepro, oral antihistamines) before approving coverage
• Quantity limits restricting fills to one bottle per 30 days

Medicare Part D plans typically list Dymista as Tier 4 with copays that can exceed $75.

Generic vs. Brand Availability

With Mylan's exit, the generic market has contracted. However, brand-name Dymista remains available from Viatris. When writing prescriptions, consider:

• Specifying "DAW" (Dispense As Written) for brand-name Dymista if the generic is consistently unavailable for your patient
• Alternatively, writing for the generic and allowing substitution — the pharmacy will fill whichever version they have in stock
• Noting both brand and generic names on the prescription to give the pharmacy maximum flexibility

Patient Cost Considerations

Cost remains a significant barrier for many patients:

• Brand Dymista cash price: $200–$300 per 30-day supply
• Generic cash price: $150–$250; as low as $46–$54 with discount coupons
• Dymista Copay Relief Card: Eligible commercially insured patients pay as low as $29 (max benefit $150 per fill)
• Viatris Patient Assistance: Available for uninsured/underinsured patients

Consider discussing cost with patients proactively, especially those who may face coverage gaps or high out-of-pocket costs.

Current Availability Picture

As of early 2026:

• Brand Dymista: Generally available but may not be stocked at all pharmacy locations
• Generic Azelastine/Fluticasone: Intermittently available — supply varies significantly by region, wholesaler, and pharmacy chain
• FDA shortage status: Not currently listed on the FDA Drug Shortage Database
• ASHP status: Monitored but not classified as an active shortage

Availability tends to be better at independent pharmacies with diverse wholesaler relationships and at mail-order pharmacies with larger inventory buffers.

Cost and Access Strategies

Here are practical steps to help your patients access Azelastine/Fluticasone or appropriate alternatives:

1. Check Real-Time Pharmacy Stock

Medfinder for Providers allows you to help patients locate pharmacies with Azelastine/Fluticasone in stock in real time. This is particularly useful when a patient reports stockouts at their usual pharmacy.

2. Consider the OTC Two-Spray Alternative

For patients who cannot access Azelastine/Fluticasone, the combination of OTC Flonase (Fluticasone Propionate) and OTC Astepro Allergy (Azelastine 0.15%) provides the same two active ingredients. While not bioequivalent to the combination product, this approach is:

• Available without a prescription
• Typically $30–$45 total (vs. $200+ for Dymista)
• Not subject to prior authorization or step therapy

Note that the azelastine concentration in Astepro (0.15%) differs from that in Dymista (0.1% equivalent), so the delivered dose per spray is somewhat different.

3. Prescribe Alternative Intranasal Corticosteroids

If the combination product isn't necessary for a particular patient, consider:

• Mometasone Furoate (Nasonex) — available OTC and as a prescription generic
• Triamcinolone Acetonide (Nasacort) — available OTC
• Budesonide (Rhinocort) — available OTC

These provide the anti-inflammatory component and may be sufficient for patients with primarily congestive symptoms.

4. Support Prior Authorization When Needed

If Azelastine/Fluticasone is clinically indicated and the insurer requires prior authorization, document:

• Duration and severity of allergic rhinitis symptoms
• Failure of OTC monotherapy (Flonase, Nasacort, oral antihistamines)
• Clinical rationale for combination therapy
• Any relevant comorbidities (asthma, nasal polyps, etc.)

Tools and Resources for Your Practice

• Medfinder for Providers — real-time pharmacy stock search to help patients find medications
• Dymista Copay Relief Card — dymista.com — for commercially insured patients
• Viatris Patient Assistance — for uninsured/underinsured patients
• NeedyMeds and RxAssist — additional patient assistance program databases

Looking Ahead

The Azelastine/Fluticasone market is likely to stabilize as remaining manufacturers adjust production and potentially new generic entrants emerge. However, in the near term:

• Expect continued intermittent availability, especially during peak allergy months (March–June)
• Insurance coverage may continue to tighten as payers push patients toward OTC alternatives
• The OTC availability of both individual components gives patients a viable fallback

Proactive communication with patients about backup plans and cost-saving strategies can prevent treatment gaps and improve adherence.

Final Thoughts

The Azelastine/Fluticasone supply situation in 2026 requires providers to be more informed and proactive than usual. By understanding the market dynamics, having conversations about cost, and using tools like Medfinder to locate available stock, you can help ensure your patients don't miss a beat during allergy season.

For patient-facing resources you can share, see our guides on the shortage update for patients and how to find Azelastine/Fluticasone in stock.